Substitute for form 1449A&B/PTO				Complete if Known		
				Application Number	10/670,915	
INFORMATION DISCLOSURE				Filing Date	September 24, 2003	
(Use as many sheets as necessary)			ANT	First Named Inventor	Daifuku, Richard	
				Art Unit	1623	
			•	Examiner Name	Devesh Khare	
Sheet	1 *	of	2	Attorney Docket Number	021227-000310US	

\subset	34
	4122110

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
/ESO/	1	US-3,907,779 3-7883314	10-26-1976	Argoudelis, et al.	Figures Appear	
/ESO/	2	US-4,171,431	10-16-1979	Skulnick		
/ESO/	3	US-4,587,117	05-06-1986	Edgren, et al.		
/ESO/	4	US-5,696,277	12-09-1997	Hostetler, et al.	*	
/ESO/	5	US-6,852,334	02-08-2005	Cullis, et al.		
					<u> </u>	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite I Cite I		T²		
/ESO/	6	BOUCHARD et al., "5-azacytidine and 5-azadeoxycytidine inhibit human immunodeficiency virus type 1 replication in vitro." <i>Antimicrobial Agents and Chemotherapy</i> , Vol. 34, pp. 206-209, Feb. 1990.			
/ESO/	7	HALLE, "5-azacytidine as a mutagen for arboviruses." <i>Journal of Virology</i> ., pp. 1228-1229, Oct. 1968.			
/ESO/	8	JOHNSON-THOMPSON et al., "Azapyrimidine analogues: Inhibition of viral DNA synthesis and protein synthesis in SV40 infected BSC-1 cells." In Vitro Cellular & Developmental Biology, Vol. 24, No. 11, pp.1114-1120, Nov. 1988.			
/ESO/	9	KEDZIERSKA et al., "Cytokines and HIV-1: interactions and clinical implications." <i>Antiviral Chemistry & Chemotherapy</i> , Vol. 12, pp. 133-150, 2001.			
/ESO/	10	NOVOTNY et al., "Polarographic reduction and potential carcinogenity of substituted 1,3,5-triazine nucleosides." Collec. Czech. Chem. Commun. Vol. 60, pp. 1,469-1475, 1995.			
/ESO/	11	PATHAK et al., "5-azacytidine and RNA secondary structure increase the retrovirus mutation rate." <i>Journal of Virology</i> , pp.3093-3100, May 1992.			

Examiner Signature	/Eric Olson/	Date Considered	11/21/2008
-----------------------	--------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.